Medical Editor: John P. Cunha, DO, FACOEP
Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets) is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 17 years of age. Common side effects of Cotempla XR-ODT include:
- decreased appetite,
- abdominal pain,
- weight loss,
- mood swings,
- fast heart rate, and
- increased blood pressure.
The recommended starting dose of Cotempla XR-ODT for pediatric patients 6 to 17 years of age is 17.3 mg given orally once daily in the morning. Dosage may be increased weekly in increments of 8.6 mg to 17.3 mg per day. Cotempla XR-ODT may interact with monoamine oxidase inhibitors (MAOIs), H2-blockers, and proton pump inhibitors (PPIs). Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Cotempla XR-ODT; it is unknown how it may affect a fetus. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to Cotempla XR-ODT during pregnancy. It is believed Cotempla XR-ODT passes into breast milk. Consult your doctor before breastfeeding. Withdrawal symptoms may occur if you suddenly stop taking Cotempla XR-ODT.
Our Cotempla XR-ODT (methylphenidate extended-release orally disintegrating tablets) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
The following are discussed in more detail in other sections of the labeling:
- Known hypersensitivity to methylphenidate or other ingredients of Cotempla XR-ODT [see CONTRAINDICATIONS]
- Hypertensive crisis when used concomitantly with monoamine oxidase inhibitors [see CONTRAINDICATIONS and DRUG INTERACTIONS]
- Drug dependence [see BOX WARNING, WARNINGS AND PRECAUTIONS, and Drug Abuse And Dependence]
- Serious cardiovascular reactions [see WARNINGS AND PRECAUTIONS]
- Blood pressure and heart rate increases [see WARNINGS AND PRECAUTIONS]
- Psychiatric adverse reactions [see WARNINGS AND PRECAUTIONS]
- Priapism [see WARNINGS AND PRECAUTIONS]
- Peripheral vasculopathy, including Raynaud’s phenomenon [see WARNINGS AND PRECAUTIONS]
- Long-term suppression of growth [see WARNINGS AND PRECAUTIONS]
Clinical Trial Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
Clinical Trials Experience With Other Methylphenidate Products In Children, Adolescents, And Adults With ADHD
Commonly reported (≥2% of the methylphenidate group and at least twice the rate of the placebo group) adverse reactions from placebo-controlled trials of methylphenidate products include: appetite decreased, weight decreased, nausea, abdominal pain, dyspepsia, dry mouth, vomiting, insomnia, anxiety, nervousness, restlessness, affect lability, agitation, irritability, dizziness, vertigo, tremor, blurred vision, blood pressure increased, heart rate increased, tachycardia, palpitations, hyperhidrosis, and pyrexia.
Clinical Trials Experience With COTEMPLA XR-ODT In Children With ADHD
There is limited experience with COTEMPLA XR-ODT in controlled trials. Based on this limited experience, the adverse reaction profile of COTEMPLA XR-ODT appears similar to other methylphenidate extended release-products.
The following adverse reactions have been identified during post approval use of methylphenidate products. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These adverse reactions are as follows:
General Disorders: Chest pain, Chest discomfort, Hyperpyrexia
Immune System Disorders: Hypersensitivity reactions such as Angioedema, Anaphylactic reactions, Auricular swelling, Bullous conditions, Exfoliative conditions, Urticarias, Pruritis NEC, Rashes, Eruptions, and Exanthemas NEC
Vascular Disorders: Raynaud’s phenomenon
Read the entire FDA prescribing information for Cotempla XR ODT (Methylphenidate Extended-Release Orally Disintegrating Tablets)
© Cotempla XR ODT Patient Information is supplied by Cerner Multum, Inc. and Cotempla XR ODT Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.